perifosine has been researched along with pomalidomide in 2 studies
| Studies (perifosine) | Trials (perifosine) | Recent Studies (post-2010) (perifosine) | Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) |
|---|---|---|---|---|---|
| 245 | 31 | 140 | 623 | 121 | 552 |
| Protein | Taxonomy | perifosine (IC50) | pomalidomide (IC50) |
|---|---|---|---|
| DNA damage-binding protein 1 | Homo sapiens (human) | 2.1 | |
| Protein cereblon | Homo sapiens (human) | 1.85 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Amm, J; Tabbara, IA | 1 |
| Orlowski, RZ | 1 |
2 review(s) available for perifosine and pomalidomide
| Article | Year |
|---|---|
Emerging therapies in multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Signal Transduction; Thalidomide | 2015 |
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |